Hormonal Therapies

FDA Approves Triptodur for Treatment of Patients 2 Years and Older with Central Precocious Puberty

ATLANTA and LAUSANNE, Switzerland, June 30, 2017 /PRNewswire/ — Arbor Pharmaceuticals, LLC, a U.S.-based specialty pharmaceutical company, and Debiopharm International SA, part of Debiopharm Group™, a Swiss-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved Triptodur™ for the treatment of pediatric patients 2 …

Read More »

Hormonal Contraceptives Linked to an Increased Risk of Rare Brain Cancer

Long-term use of contraceptive pills may double the risk of developing brain cancer, according to a new study. Scientists say that taking hormonal contraception, particularly progesterone-only methods, for five years more than doubles the chance of developing glioma, a rare type of brain cancer which affects roughly five in 100,000 …

Read More »